Cargando…
Her-2 Targeted Therapy in Advanced Urothelial Cancer: From Monoclonal Antibodies to Antibody-Drug Conjugates
Metastatic urothelial cancer, associated with a poor prognosis, is still major cause of cancer-related death, with scarce options of effective treatment after progression to platinum-based chemotherapy and immunotherapy. The human epithelial growth factor receptor 2 (Her-2) has been identified as a...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9603928/ https://www.ncbi.nlm.nih.gov/pubmed/36293515 http://dx.doi.org/10.3390/ijms232012659 |
_version_ | 1784817680238247936 |
---|---|
author | Albarrán, Víctor Rosero, Diana Isabel Chamorro, Jesús Pozas, Javier San Román, María Barrill, Ana María Alía, Víctor Sotoca, Pilar Guerrero, Patricia Calvo, Juan Carlos Orejana, Inmaculada Pérez de Aguado, Patricia Gajate, Pablo |
author_facet | Albarrán, Víctor Rosero, Diana Isabel Chamorro, Jesús Pozas, Javier San Román, María Barrill, Ana María Alía, Víctor Sotoca, Pilar Guerrero, Patricia Calvo, Juan Carlos Orejana, Inmaculada Pérez de Aguado, Patricia Gajate, Pablo |
author_sort | Albarrán, Víctor |
collection | PubMed |
description | Metastatic urothelial cancer, associated with a poor prognosis, is still major cause of cancer-related death, with scarce options of effective treatment after progression to platinum-based chemotherapy and immunotherapy. The human epithelial growth factor receptor 2 (Her-2) has been identified as a new therapeutic target in medical oncology. However, despite the encouraging results in breast and gastric cancers, clinical trials with anti-Her-2 monoclonal antibodies and tyrosine-kinase inhibitors have shown limited efficacy of this strategy in urothelial tumors. Notably, more favorable data have been recently shown that antibody-drug conjugates are currently emerging as a novel promising approach for Her-2 targeted therapy in advanced urothelial cancer. |
format | Online Article Text |
id | pubmed-9603928 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-96039282022-10-27 Her-2 Targeted Therapy in Advanced Urothelial Cancer: From Monoclonal Antibodies to Antibody-Drug Conjugates Albarrán, Víctor Rosero, Diana Isabel Chamorro, Jesús Pozas, Javier San Román, María Barrill, Ana María Alía, Víctor Sotoca, Pilar Guerrero, Patricia Calvo, Juan Carlos Orejana, Inmaculada Pérez de Aguado, Patricia Gajate, Pablo Int J Mol Sci Review Metastatic urothelial cancer, associated with a poor prognosis, is still major cause of cancer-related death, with scarce options of effective treatment after progression to platinum-based chemotherapy and immunotherapy. The human epithelial growth factor receptor 2 (Her-2) has been identified as a new therapeutic target in medical oncology. However, despite the encouraging results in breast and gastric cancers, clinical trials with anti-Her-2 monoclonal antibodies and tyrosine-kinase inhibitors have shown limited efficacy of this strategy in urothelial tumors. Notably, more favorable data have been recently shown that antibody-drug conjugates are currently emerging as a novel promising approach for Her-2 targeted therapy in advanced urothelial cancer. MDPI 2022-10-21 /pmc/articles/PMC9603928/ /pubmed/36293515 http://dx.doi.org/10.3390/ijms232012659 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Albarrán, Víctor Rosero, Diana Isabel Chamorro, Jesús Pozas, Javier San Román, María Barrill, Ana María Alía, Víctor Sotoca, Pilar Guerrero, Patricia Calvo, Juan Carlos Orejana, Inmaculada Pérez de Aguado, Patricia Gajate, Pablo Her-2 Targeted Therapy in Advanced Urothelial Cancer: From Monoclonal Antibodies to Antibody-Drug Conjugates |
title | Her-2 Targeted Therapy in Advanced Urothelial Cancer: From Monoclonal Antibodies to Antibody-Drug Conjugates |
title_full | Her-2 Targeted Therapy in Advanced Urothelial Cancer: From Monoclonal Antibodies to Antibody-Drug Conjugates |
title_fullStr | Her-2 Targeted Therapy in Advanced Urothelial Cancer: From Monoclonal Antibodies to Antibody-Drug Conjugates |
title_full_unstemmed | Her-2 Targeted Therapy in Advanced Urothelial Cancer: From Monoclonal Antibodies to Antibody-Drug Conjugates |
title_short | Her-2 Targeted Therapy in Advanced Urothelial Cancer: From Monoclonal Antibodies to Antibody-Drug Conjugates |
title_sort | her-2 targeted therapy in advanced urothelial cancer: from monoclonal antibodies to antibody-drug conjugates |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9603928/ https://www.ncbi.nlm.nih.gov/pubmed/36293515 http://dx.doi.org/10.3390/ijms232012659 |
work_keys_str_mv | AT albarranvictor her2targetedtherapyinadvancedurothelialcancerfrommonoclonalantibodiestoantibodydrugconjugates AT roserodianaisabel her2targetedtherapyinadvancedurothelialcancerfrommonoclonalantibodiestoantibodydrugconjugates AT chamorrojesus her2targetedtherapyinadvancedurothelialcancerfrommonoclonalantibodiestoantibodydrugconjugates AT pozasjavier her2targetedtherapyinadvancedurothelialcancerfrommonoclonalantibodiestoantibodydrugconjugates AT sanromanmaria her2targetedtherapyinadvancedurothelialcancerfrommonoclonalantibodiestoantibodydrugconjugates AT barrillanamaria her2targetedtherapyinadvancedurothelialcancerfrommonoclonalantibodiestoantibodydrugconjugates AT aliavictor her2targetedtherapyinadvancedurothelialcancerfrommonoclonalantibodiestoantibodydrugconjugates AT sotocapilar her2targetedtherapyinadvancedurothelialcancerfrommonoclonalantibodiestoantibodydrugconjugates AT guerreropatricia her2targetedtherapyinadvancedurothelialcancerfrommonoclonalantibodiestoantibodydrugconjugates AT calvojuancarlos her2targetedtherapyinadvancedurothelialcancerfrommonoclonalantibodiestoantibodydrugconjugates AT orejanainmaculada her2targetedtherapyinadvancedurothelialcancerfrommonoclonalantibodiestoantibodydrugconjugates AT perezdeaguadopatricia her2targetedtherapyinadvancedurothelialcancerfrommonoclonalantibodiestoantibodydrugconjugates AT gajatepablo her2targetedtherapyinadvancedurothelialcancerfrommonoclonalantibodiestoantibodydrugconjugates |